Kyverna Therapeutics, Inc.
KYTX
$9.40
$0.040.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -341.95% | -14.96% | |||
| Gross Profit | 341.95% | 14.96% | |||
| SG&A Expenses | 12.07% | -3.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.43% | -12.80% | |||
| Operating Income | -1.43% | 12.80% | |||
| Income Before Tax | -2.76% | 12.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.76% | 12.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.76% | 12.58% | |||
| EBIT | -1.43% | 12.80% | |||
| EBITDA | -1.18% | -71.97% | |||
| EPS Basic | 5.38% | 12.96% | |||
| Normalized Basic EPS | 5.38% | 12.97% | |||
| EPS Diluted | 5.38% | 12.96% | |||
| Normalized Diluted EPS | 5.38% | 12.97% | |||
| Average Basic Shares Outstanding | 8.62% | 0.44% | |||
| Average Diluted Shares Outstanding | 8.62% | 0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||